Secretin Trial NCT06874270 on Obesity Therapy Terminated

A clinical trial involving secretin was updated with a status change on July 7, 2026. The study, titled "Metabolic Phenotyping for Personalized Obesity Therapy," is registered under ClinicalTrials.gov identifier NCT06874270. Its current status is listed as terminated. No phase information was provided in the available record. The event data does not specify a reason for termination. No results or outcome data are included in this update. This brief reports only the status change as recorded and does not describe or imply any efficacy, safety findings, or causes related to the termination. Readers seeking further detail on the trial's design, enrollment, or termination rationale should consult the official ClinicalTrials.gov listing directly. Secretin remains an approved compound, and this update pertains specifically to its investigation in the context of personalized obesity therapy research. For general background on secretin, readers can refer to the compound overview.